The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2020Identification and Characterization of Small Molecule Activators of ATP13A2 for Parkinson’s Disease Therapy
Study Rationale:
In Parkinson’s disease, neurons degenerate because of a disturbed function of the lysosomes and mitochondria. The lysosomal transporter ATP13A2 (PARK9) is genetically implicated in... -
Target Advancement Program, 2020Identification of ASC as a Disease-modifying Therapeutic Target in Parkinson’s Disease
Study Rationale:
Inflammasomes are large multiprotein complexes that play a central role in the innate immune system, the body’s first line of defense against microbes. Inflammasomes are key drivers... -
Research Grant, 2020Discovery of Selective PET Imaging Agents for Tauopathies and Alpha-Synuclein
Study Rationale:
For reasons not yet understood, a protein called alpha-synuclein clumps in the brain cells of people with Parkinson’s disease. Some evidence suggests that a protein called tau also... -
Biosample Use Program, 2020Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD
Study Rationale:
Mutations in a gene called LRRK2 can cause Parkinson's disease but only a quarter to half of the people who carry one of these mutations will actually develop Parkinson’s in their... -
Therapeutic Pipeline Program, 2020Developing TMEM175 Activators as Therapeutics for Parkinson's Disease
Study Rationale:
Our aim is to develop a drug that will slow or stop the progression of Parkinson’s disease in patients who carry a mutation in the TMEM175 gene. The TMEM175 gene produces a... -
Biosample Use Program, 2020CSF RT-QuIC Alpha-Synuclein Amplification in LRRK2-Parkinson’s Disease
Study Rationale:
Parkinson’s disease caused by genetic mutations in the gene called leucine rich repeat kinase 2 (LRRK2) is clinically indistinguishable from idiopathic Parkinson’s disease, in which...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.